An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Dry Eye

In brief

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Key facts

Study ID

NCT07179055

Run by

Vanda Pharmaceuticals

People needed

160

Starts

2025-10-01

Expected to finish

2026-09-01

Last updated by the study team

2025-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be at least 18 years of age of either gender and any race.
• Provide written informed consent and sign the HIPAA form.
• Be willing and able to follow all instructions and attend all study visits.

You may not qualify if…

• Use of any of the disallowed medications during the washout and study period.

Where it is running

• Vanda Investigational Site — Newport Beach, California, United States (enrolling)
• Vanda Investigational Site — Memphis, Tennessee, United States (enrolling)
• Vanda Investigational Site — Andover, Massachusetts, United States
• Vanda Investigational Site — Shelby, North Carolina, United States
• Vanda Investigational Site — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.